New abstract published in BMC Nephrology;

"Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab" by Alachkar N. et al.

Conclusion:

"In this study of post transplant FSGS patients managed with TPE and rituximab, the reduction of suPAR after treatment contributed significantly to the reduction in proteinuria as well as to the response to therapy. These findings support monitoring of suPAR in TPE and rituximab managed recurrent and de novo FSGS".

pdfLink to abstract here